Zejula (niraparib) — Medica

Ovarian cancer – maintenance therapy

Initial criteria

Patient is age ≥ 18 years
Patient is in complete or partial response after a platinum-based chemotherapy regimen (e.g., carboplatin with gemcitabine, carboplatin with paclitaxel, cisplatin with gemcitabine)
ONE of the following:
i. BOTH of the following:
a) Patient has recurrent disease
b) Patient has a BRCA mutation
OR
ii. BOTH of the following:
a) Patient is in complete or partial response to first-line primary treatment
b) Patient has homologous recombination deficiency (HRD)-positive disease (includes patient with a BRCA mutation)

1 year